- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Interventions
- Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–47
of 47
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- bimekizumab, ustekinumab, placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab, Ustekinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 69
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more
- Conditions
- Sarcoidosis
- Interventions
- Placebo, Golimumab, Ustekinumab
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more
- Conditions
- Plaque Psoriasis
- Interventions
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
- Conditions
- Graft vs. Host Disease
- Interventions
- Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
- Interventions
- Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab
- Drug · Other · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • Tampa, Florida • Buffalo, New York + 1 more
- Conditions
- Axial Spondyloarthritis
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
- Conditions
- Chronic Plaque Type Psoriasis
- Interventions
- AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 676 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 37
- States / cities
- Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo
- Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more
- Conditions
- Colitis, Ulcerative, Inflammatory Bowel Diseases
- Interventions
- Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 961 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more
- Conditions
- Axial Spondyloarthritis
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 19
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 26
- States / cities
- Encinitas, California • La Jolla, California • San Diego, California + 23 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Psoriasis
- Interventions
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab, Placebo
- Biological
- Lead sponsor
- MedDerm Associates
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Abatacept, UST Placebo, ABA Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more